Full-Time

Manager – IT Operations

Updated on 7/23/2026

Kyverna Therapeutics

Kyverna Therapeutics

51-200 employees

T cell therapies for autoimmune diseases

Compensation Overview

$135k - $150k/yr

+ Bonus + Stock Plan

Oakland, CA, USA

Hybrid

Hybrid role; on-site in Emeryville, California with remote work possible.

Category
IT & Security (1)
Required Skills
Sharepoint
Microsoft Intune

Get referred to Kyverna Therapeutics

Find people who can refer or advise you

Requirements
  • 10+ years of experience in IT operations, end-user support, helpdesk management, infrastructure support, or related enterprise IT functions.
  • 3+ years of experience leading, managing, mentoring, or supervising IT support teams, technical operations staff, contractors, or vendor resources.
  • Strong understanding of Microsoft 365, Windows, macOS, Apple and PC hardware, MDM, SaaS administration, identity workflows, and corporate A/V systems.
  • Proven ability to lead helpdesk operations, optimize ticket workflows, maintain SLA discipline, and communicate with technical and non-technical stakeholders.
  • Experience with IT asset management, procurement, vendor coordination, lifecycle planning, documentation, and secure support operations.
  • Ability to thrive in a fast-paced, multitasking environment and respond effectively to shifting priorities and confidential information.
Responsibilities
  • Lead daily IT operations and support delivery for helpdesk, endpoint, collaboration, and employee technology services.
  • Manage and mentor IT support staff or vendor resources, setting expectations for ticket quality, SLA performance, documentation, and customer experience.
  • Serve as escalation point for high-priority users and complex issues across Microsoft 365, Windows, macOS, mobile devices, connectivity, peripherals, and productivity tools.
  • Oversee endpoint lifecycle management, including procurement, deployment, MDM enrollment, asset tracking, repair, refresh, and retirement for Apple and Windows devices.
  • Administer and improve workflows for Microsoft 365, SharePoint, Intune, Jamf, Okta or equivalent identity tools, Zoom, Fresh Service, and other core SaaS platforms.
  • Partner with Security, Compliance, HR, Facilities, and Finance on onboarding, offboarding, access changes, device compliance, asset recovery, and audit-ready procedures.
  • Own executive, conference room, and corporate A/V support, ensuring meetings, events, and hybrid collaboration spaces are reliable and professionally supported.
  • Perform root-cause analysis for recurring incidents, access issues, endpoint problems, and support bottlenecks; recommend long-term process, automation, or training improvements.
  • Coordinate with Level 3 teams, vendors, and service providers when needed, ensuring timely and documented resolution.
  • Build and maintain IT runbooks, user guides, knowledge base content, and training materials to improve self-service and support consistency.

Kyverna Therapeutics develops cell therapies for autoimmune diseases. The company uses synthetic biology, immunology, and cell engineering to create engineered T cells designed to target and modulate the root causes of autoimmunity. Its therapies are intended to be given by a single infusion to achieve long-lasting disease control, reducing or eliminating the need for ongoing treatments. Kyverna pursues in-licensing and collaboration opportunities to broaden its technology and capabilities and to advance its therapies toward patients through development and sales to patients and healthcare providers. The core goal is to provide durable, well-tolerated treatments that can offer substantial, long-term relief for people with autoimmune diseases.

Company Size

51-200

Company Stage

IPO

Headquarters

Emeryville, California

Founded

2018

Get referred to Kyverna Therapeutics

Find people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • miv-cel could become first FDA-approved CAR T therapy for autoimmune disease in 2026.
  • Updated Phase 2 data showed 81% symptom improvement in stiff-person syndrome patients.
  • Generalized myasthenia gravis data showed 100% patients achieved rapid, sustained clinical benefit.

What critics are saying

  • SPS Phase 2 topline data in early 2026 may fail efficacy or safety thresholds.
  • Organizers may delay BLA due to insufficient long-term safety data from 52-week follow-up.
  • COMPARE trial may lose to rituximab, invalidating immune reset narrative and blocking RA expansion.

What makes Kyverna Therapeutics unique

  • Kyverna is the first company advancing CAR T-cell therapy for autoimmune disease.
  • Its miv-cel targets B cells to reset the immune system after single infusion.
  • Unlike chronic treatments, one infusion aims for durable, drug-free remission in patients.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Remote Work Options

Performance Bonus

Growth & Insights

Headcount

6 month growth

1%

1 year growth

0%

2 year growth

4%